Q2 2026 13F · SEC CIK 1475373

Sector Gamma As

Investment managerFiled 2026-08-12 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $461.0M
Reported positions: 40
Top holdings a year, 3 yrs: +17.0%
Average holding period: 5.6 yrs

Sector Gamma As is an investment manager that reported 40 positions worth $461.0M in its Q2 2026 13F, filed 2026-08-12. Its largest holdings were Bristol-Myers Squibb Co (BMY, 9.1%), Merck & Co Inc (MRK, 6.0%), Medtronic PLC (MDT, 6.0%). A portfolio copying its top holdings returned 17.0% a year over the last 3 years, against 22.3% for the S&P 500.

Sector Gamma As holdings all 40 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Sector Gamma As 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
BMYBristol-Myers Squibb Co	9.1%	11.9%	726,115	-12.3%	$41.8M
MRKMerck & Co Inc	6.0%	7.4%	217,008	-16.6%	$27.9M
MDTMedtronic PLC	6.0%	5.7%	352,437	+25.6%	$27.6M
PFEPfizer Inc	5.2%	7.2%	1,004,215	-8.0%	$24.2M
INCYIncyte Corp	4.2%	4.5%	170,753	-14.8%	$19.4M
ELVElevance Health Inc Formerly	3.7%	3.0%	44,499	+1.2%	$17.2M
BMRNBiomarin Pharmaceutical Inc	3.7%	3.2%	294,918	+22.9%	$16.9M
TMOThermo Fisher Scientific Inc	3.7%	New	33,584	—	$16.8M
CVSCvs Health Corp	3.5%	2.3%	155,337	+14.8%	$16.1M
IQVIqvia Hldgs Inc	3.3%	1.6%	77,944	+93.7%	$15.1M
IONSIonis Pharmaceuticals Inc	3.3%	3.0%	189,468	+11.8%	$15.0M
BDXBecton Dickinson & Co	3.1%	3.1%	93,168	+12.8%	$14.1M
ABTAbbott Laboratories	2.9%	2.1%	147,444	+68.4%	$13.4M
GEHCGe Healthcare Technologies I	2.9%	2.1%	207,863	+64.4%	$13.3M
ZBHZimmer Biomet Holdings Inc	2.7%	3.3%	142,307	-8.7%	$12.3M
BIIBBiogen Inc	2.5%	3.9%	54,163	-39.9%	$11.7M
QGENQiagen NV	2.4%	1.5%	287,640	+77.1%	$11.2M
CNCCentene Corp Del	2.3%	1.3%	162,405	+0.0%	$10.4M
REGNRegeneron Pharmaceuticals	2.1%	New	15,780	—	$9.8M
BIOBio Rad Labs Inc	2.1%	1.6%	33,350	+40.4%	$9.8M
CAHCardinal Health Inc	2.1%	2.7%	40,689	-25.9%	$9.7M
AMGNAmgen Inc	2.1%	3.9%	26,281	-44.3%	$9.5M
BRKRBruker Corp	2.0%	2.2%	152,352	-40.0%	$9.2M
AVTRAvantor Inc	1.9%	1.3%	906,088	+30.3%	$9.0M
PTCTPtc Therapeutics Inc	1.8%	1.2%	100,000	+33.3%	$8.2M
LHLabcorp Holdings Inc	1.6%	1.2%	26,019	+36.8%	$7.3M
DXCMDexcom Inc	1.5%	0.8%	102,122	+82.0%	$6.9M
ASNDAscendis Pharma A/s	1.2%	New	21,305	—	$5.7M
EWEdwards Lifesciences Corp	1.2%	1.1%	60,402	+0.0%	$5.5M
SNDXSyndax Pharmaceuticals Inc	1.1%	1.6%	241,739	-15.5%	$5.3M
BSXBoston Scientific Corp	1.1%	New	121,128	—	$5.2M
KURAKura Oncology Inc	1.0%	0.8%	433,012	+5.1%	$4.8M
TVTXTravere Therapeutics Inc	1.0%	New	80,000	—	$4.5M
CRNXCrinetics Pharmaceuticals in	0.9%	0.8%	114,628	+21.7%	$4.3M
TNDMTandem Diabetes Care Inc	0.9%	1.2%	267,091	+0.0%	$4.0M
IOVAIovance Biotherapeutics Inc	0.9%	0.7%	968,466	+7.6%	$4.0M
CYTKCytokinetics	0.8%	New	45,000	—	$3.8M
OGNOrganon & Co	0.8%	0.5%	270,781	-28.0%	$3.7M
ARDXArdelyx Inc	0.8%	0.7%	686,844	+33.1%	$3.5M
NTLAIntellia Therapeutics Inc	0.7%	New	185,177	—	$3.1M

What Sector Gamma As bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +31.5% /yr; S&P 500 +11.7%
3 years: +17.0% /yr; S&P 500 +22.3%
5 years: +9.9% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$461.0M	40
Q1 2026	$423.5M	42
Q4 2025	$438.7M	36
Q3 2025	$403.3M	41
Q2 2025	$305.9M	38
Q1 2025	$312.2M	33
Q4 2024	$290.9M	30
Q3 2024	$329.6M	29
Q2 2024	$267.7M	28
Q1 2024	$354.8M	28
Q4 2023	$412.1M	30
Q3 2023	$391.3M	28

Questions about Sector Gamma As's portfolio

What stocks does Sector Gamma As own?

Sector Gamma As's latest 13F, for Q2 2026 and filed Aug 12, 2026, lists 40 positions worth $461.0M. The largest are Bristol-Myers Squibb Co (BMY) at 9.1%, Merck & Co Inc (MRK) at 6.0%, Medtronic PLC (MDT) at 6.0%, Pfizer Inc (PFE) at 5.2% and Incyte Corp (INCY) at 4.2%.

What did Sector Gamma As buy last quarter?

In Q2 2026, Sector Gamma As added a new position in Thermo Fisher Scientific Inc (TMO), a new position in Regeneron Pharmaceuticals (REGN), a new position in Ascendis Pharma A/s (ASND), a new position in Boston Scientific Corp (BSX), a new position in Travere Therapeutics Inc (TVTX), Iqvia Hldgs Inc (IQV) (+93.7% shares), Dexcom Inc (DXCM) (+82.0% shares) and Qiagen NV (QGEN) (+77.1% shares), compared with its Q1 2026 filing.

What did Sector Gamma As sell last quarter?

In Q2 2026, Sector Gamma As sold all of Unitedhealth Group Inc (UNH), sold all of Gilead Sciences Inc (GILD), sold all of Lantheus Hldgs Inc (LNTH), sold all of Ascendis Pharma A/s, sold all of Humana Inc (HUM), Amgen Inc (AMGN) (-44.3% shares), Bruker Corp (BRKR) (-40.0% shares) and Biogen Inc (BIIB) (-39.9% shares), compared with its Q1 2026 filing.

How has Sector Gamma As's portfolio performed?

A portfolio copying Sector Gamma As's 20 largest 13F holdings each quarter, from the day each filing was public, returned +17.0% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +31.5% against +11.7%. Over 5 years: +9.9% a year against +10.6%.

When is Sector Gamma As's next 13F filing due?

13F filings are due 45 days after each quarter ends. Sector Gamma As's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.